Oragenics, Inc. Prepares Drug for Phase II Clinical Trials to Treat Concussion
The drug candidate is expected to be combined with its novel intranasal device, for the treatment of mild Traumatic Brain Injury, aka concussion.
- The drug candidate is expected to be combined with its novel intranasal device, for the treatment of mild Traumatic Brain Injury, aka concussion.
- A 40-patient Phase I human study showed ONP-002 to be safe and well-tolerated.
- Phase II patients will be recruited between the ages of 18-55 in the acute phase following concussion.
- “Preclinical intranasal targeting of the brain has been shown to improve outcomes in animals and safety margin following concussion.